<DOC>
	<DOC>NCT00735644</DOC>
	<brief_summary>This study is to assess the safety and immunogenicity of three consecutive lots of JE-CV in toddlers aged 12-18 months. Primary objective: To demonstrate the bio-equivalence of three lots of JE-CV vaccine manufactured by sanofi pasteur. Secondary objective: To describe the safety of vaccination in all subjects</brief_summary>
	<brief_title>Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines</brief_title>
	<detailed_description>This is a Phase III trial in toddlers in Thailand and the Philippines.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Encephalitis, Japanese</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Aged 12 to 18 months on the day of inclusion. In good general health, without significant medical history. Provision of informed consent form signed by at least one parent or other legally acceptable representative, and by at least one independent witness if required by local regulations. Subject and parent/legally acceptable representative able to attend all scheduled visits and comply with all trial procedures. Completion of vaccinations according to the national immunization schedule. Exclusion Criteria : Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the trial vaccination. Planned participation in another clinical trial during the present trial period. Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anticancer chemotherapy or radiation therapy within the preceding 6 months, or longterm systemic corticosteroids therapy. Known systemic hypersensitivity to any of the vaccine components or history of a lifethreatening reaction to a vaccine containing any of the same substances. Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator. Receipt of blood or bloodderived products in the past 3 months, that might interfere with the assessment of the immune response. Administration of any antiviral within 2 months preceding V01. History of central nervous system disorder or disease, including seizures. Personal or family history of thymic pathology (thymoma), thymectomy, or myasthenia. Receipt of any vaccine in the 4 weeks preceding the first trial vaccination. Planned receipt of any vaccine in the 4 weeks following any trial vaccination. Personal human immunodeficiency virus seropositivity in the blood sample taken at screening. Receipt of any JE vaccine or hepatitis A vaccine. Previous vaccination against flavivirus disease. History of flavivirus infection (confirmed either clinically, serologically or microbiologically) Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion contraindicating intramuscular vaccination. Febrile illness (temperature ≥38°C) or moderate or severe acute illness/infection on the day of vaccination, according to Investigator judgment.</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Japanese encephalitis, Hepatitis A, Inactivated Mouse-Brain</keyword>
</DOC>